Secondary Progressive Multiple Sclerosis

Patients with active secondary progressive MS who received high-efficacy therapy experienced relapses less often than those on low-efficacy therapy, according to findings published in Neurology.

The timed 25-foot walk test and the nine-hole peg test demonstrated lower rates of improvement than the Expanded Disability Scale Status, which is consistent with less measurement error, according to findings published in Neurology.

Treatment with masitinib, a first-in-class tyrosine kinase inhibitor, led to significant improvement in Expanded Disability Scale Status, or EDSS, for patients with MS, according to findings presented at MSVirtual2020.

Patients with secondary progressive MS on disease-modifying treatments often are clinically misclassified as having relapsing-remitting MS, most likely because they are not reassigned categorically until after conversion has occurred.

A blood test may be able to identify patients with multiple sclerosis who are more likely to have worsening disability, according to research published in Neurology, the medical journal of the American Academy of Neurology.